Erratum: Increased regulatory activity of the calcinerum/NFAT pathway in human heart failure (European Journal of Heart Failure (2004) 6 (3-9) DOI: 10.1016/j.ejheart.2003.07.007;Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure

European Journal of Heart Failure

Volumn 6, Issue 1, 2004, Pages 3-9

  Diedrichs, Holger ^a   Chi, Mei ^a   Boelck, Birgit ^a   Mehlhorm, Uwe ^a   Schwinger, Robert H G ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Calcineurin; Cardiomyopathy; GATA 4; Heart failure; Hypertrophy; NFAT 3

Indexed keywords

CALCINEURIN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NFAT;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; EXTRACTION; FEMALE; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE; HOMOGENATE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MICRODENSITOMETRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0842326416     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.10.001     Document Type: Erratum

References (25)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J Med. 322:1990;1561-1566.
2. Kaab S., Dixon J., Duc J., et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation. 98:1998;1383-1393.
3. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbbins J., Grant S.R., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
4. Molkentin J.D., Olson E.N. GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation. 96:1997;3833-3835.
5. Mably J.D., Liew C.C. Factors involved in cardiogenesis and the regulation of cardiac-specific gene expression. Circ Res. 79:1996;4-13.
6. Olson E.N., Molkentin J.D. Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? Circ Res. 84:1999;623-632.
7. Sussman M.A. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 281:1998;1690-1693.
8. Meguro T. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res. 84:1999;735-740.
9. Luo Z., Shyu K.G., Gulaberto A., Walsh K. Calcineurin inhibitors and cardiac hypertrophy. Nat Med. 10:1998;1092-1093.
10. Muller J.G., Nemoto S., Laser M., Carabello B.A., Menick D.R. Calcineurin inhibition and cardiac hypertrophy [letter]. Science. 282:1998;1007.
11. Zhang W., Kowal R.C., Rusnak F., Sikkink R.A., Olson E.N., Victor R.G. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res. 84:1999;722-728.
12. Ding B., Price R.L., Borg T.K. Pressure overload induces several hypertrophy in mice treated with cyctosporin, an inhibitor of calcineurin. Circ Res. 84:1999;729-734.
13. Rothermel B.A., McKinsey T.A., Olson E.N., Williams R., et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. PNAS. 98:(6):2001;3328-3333.
14. Lim H.W., Molkentin J.D. Calcineurin and human heart failure. Nat Med. 5:1999;246-247.
15. Ritter O., Hack S., Schuh K., Rothlein N., Perrot A., Osterziel K.J., et al. Calcineurin in human heart hypertrophy. Circulation. 105:(19):2002;2265.
16. Tsao L., Neville C., Musaro A., McCullagh K.J., Rosenthal N. Revisiting calcineurin and human heart failure. Nat Med. 6:2000;2-3.
17. Haq S., Choukroun G., Lim H., Tymitz K.M., Monte F., Gwathmey J., et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 103:2001;670-677.
18. Boelck B., Munch G., Karczewski P., Schwinger R.H. Evidence for calcineurin-mediated regulation of SERCA 2a activity in human myocardium. J Mol Cell Cardiol. 34:(3):2002;321-334.
19. 2+ response amplitude and duration. Nature. 386:1997;855-858.
20. Munch G., Boick B., Sugaru A., Brixius K., Bloch W., Schwinger R.H. Increased expression of isoform 1 of the sarcoplasmic reticulum Ca(2+)-release channel in failing human heart. Circulation. 103:(22):2001;2739-2744.
21. 2+ exchanger protein levels in human heart failure. Circulation. 99:(16):1999;2105-2112.
22. Sugden P.H. Signaling in myocardial hypertrophy: life after calcineurin? Circ Res. 84:1999;633-646.
23. MacLellan R. Advances in the molecular mechanisms of heart failure. Curr Opin Cardiol. 15:2000;128-135.
24. Stemmer P.M., Klee C.B. Dual calcium ion regulation of cacineurin by calmodulin and calcineurin B. Biochemitry. 33:1994;6859-6866.
25. Hautala N., Tokola H., Luodonpaa M., Puhakka J., Romppanen H., Vuolteenaho O., et al. Pressure overload increase GATA-4 binding activity via endothelin-1'. Circulation. 5:2001;730-735.